| Literature DB >> 25838942 |
Abstract
To evaluate the effects of filtering short wavelength light on visual performance under intense light conditions among pseudophakic patients previously implanted with a clear intraocular lens (IOL). This was a patient-masked, randomized crossover study conducted at 6 clinical sites in the United States between September 2013 and January 2014. One hundred fifty-four bilaterally pseudophakic patients were recruited. Photostress recovery time and glare disability thresholds were measured with clip-on blue-light-filtering and placebo (clear; no blue-light filtration) glasses worn over patients' habitual correction. Photostress recovery time was quantified as the time necessary to regain sight of a grating target after intense light exposure. Glare disability threshold was assessed as the intensity of a white-light annulus necessary to obscure a central target. The order of filter used and test eye were randomized across patients. Photostress recovery time and glare disability thresholds were significantly improved (both P < 0.0001) when patients used blue-light-filtering glasses compared with clear, nonfiltering glasses. Compared with a nonfiltering placebo, adding a clip-on blue-absorbing filter to the glasses of pseudophakic patients implanted with clear IOLs significantly increased their ability to cope with glare and to recover normal viewing after an intensive photostress. This result implies that IOL designs with blue-light-filtering characteristics may be beneficial under intense light conditions.Entities:
Year: 2015 PMID: 25838942 PMCID: PMC4370187 DOI: 10.1155/2015/607635
Source DB: PubMed Journal: J Ophthalmol ISSN: 2090-004X Impact factor: 1.909
Figure 1Schematic of the optical system used to measure disability glare thresholds and photostress recovery time. A1-A2: apertures; BS: beam splitters; D1-D2: diffusers; EC: final focusing lens and eye cup for head positioning; FH: filter holder; G: grating and aperture for defining target; L1–L3: planoconvex achromatic lenses; M: mirror; PC: photocell; S1-S2: LED light sources.
Patient demographics and baseline characteristics.
| Parameter | Patients ( |
|---|---|
| Age, y | |
| Mean ± SD | 69.8 ± 8.0 |
| Range | 48–88 |
| Sex, | |
| Female | 91 (58) |
| Male | 65 (42) |
| Race, | |
| White | 148 (95) |
| African American | 5 (3) |
| Asian | 1 (1) |
| Pacific Islander | 1 (1) |
| Other | 1 (1) |
| Pseudophakia status, months | |
| Mean ± SD | 16.3 ± 27.6 |
| Range | 3–216 |
| Spherical correction, D | |
| Mean ± SD | −0.121 ± 0.739 |
| Range | −2.75 to +2.25 |
| Cylindrical correction, D | |
| Mean ± SD | −0.015 ± 0.672 |
| Range | −2.50 to +2.25 |
| Axis,* degrees | |
| Mean ± SD | 55.8 ± 65.4 |
| Range | 0–180 |
| Intraocular lenses,†
| |
| Abbott Medical Optics‡ (Tecnis) | 114 (73) |
| Lenstec (Lenstec, Softec, and Softec HDO) | 22 (14) |
| Bausch & Lomb (Crystalens and Akreos) | 13 (8) |
| Alcon (SA60AT and SA6003) | 3 (2) |
| Hoya | 1 (1) |
| Missing | 1 (1) |
| Test eye, | |
| OD | 76 (49) |
| OS | 79 (51) |
| Missing | 1 (1) |
OD: oculus dexter (right eye); OS: oculus sinister (left eye).
* n = 115.
†1 patient had 2 different Bausch & Lomb intraocular lenses.
‡1 patient had an Abbott Medical Optics multifocal intraocular lens.
Photostress recovery time and glare disability threshold (efficacy analysis data set).
| BLF Glasses | Non-BLF Glasses | |
|---|---|---|
| Photostress recovery time, seconds | ||
|
| 145 | 144 |
| Mean ± SD | 5.66 ± 6.20 | 6.94 ± 7.16 |
| Range | 1.0–29.3 | 1.0–36.0 |
| Difference ( | −1.37 (0.00010; −2.08 to −0.66) | |
| Glare disability threshold, log units | ||
|
| 146 | 147 |
| Mean ± SD | 1.37 ± 0.88 | 1.26 ± 0.92 |
| Range | −0.6 to 3.1 | −0.6 to 4.0 |
| Difference ( | 0.12 (0.00014; 0.06–0.18) | |
BLF: blue-light filtering.
*1-sided P value from paired t-test.
Studies on blue-light intraocular filters and visual benefit.
| Study | Sample | Design | Supplement | Variables | Effect size |
|---|---|---|---|---|---|
|
| |||||
| Gray et al., | 34 adults | Case-control | n/a | GD in a driving simulator | 0.0008 versus clear IOLs |
| Gray et al., | 33 adults | Case-control | n/a | GD in a driving simulator | 0.05 versus clear IOLs |
| Hammond et al., | 58 adults | Case-control | n/a | Glare disability | 0.02 versus clear IOLs |
| Hammond et al., | 58 adults | Case-control | n/a | PS recovery | 0.01 versus clear IOLs |
| Hammond et al., | 52 adults | Contralateral | n/a | GD | 0.04 versus clear IOLs |
| Hammond et al., | 52 adults | Contralateral | n/a | PS recovery | 0.02 versus clear IOLs |
| Hammond et al., | 52 adults | Contralateral | n/a | Chromatic contrast | 0.00003 versus clear IOLs |
|
K. Hayashi and H. Hayashi, | 74 adults | Case-control | n/a | CSF under glare | Null* |
| Muftuoglu et al., | 38 adults | Case-control | n/a | GD | Null* |
| Neumaier-Ammerer et al., | 76 adults | Case-control | n/a | CSF under glare | Null* |
| Niwa et al., | 64 adults | Case-control | n/a | CSF under glare | 0.025 |
| Pandita et al., | 120 adults | Case-control | n/a | CSF under glare | Photopic = 0.005, |
|
| |||||
|
| |||||
| Hammond et al., | 150 adults | Cross-sectional | n/a | Glare disability | 0.0015 |
| Hammond et al., | 150 adults | Cross-sectional | n/a | PS recovery | 0.01 |
| Hammond et al., | 150 adults | Cross-sectional | n/a | Chromatic contrast | 0.00005 |
| Hammond et al., | 109 adults | RCT | 12 mg/1 year | PS recovery | 0.01 |
| Hammond et al., | 109 adults | RCT | 12 mg/1 year | GD | 0.21 |
| Hammond et al., | 109 adults | RCT | 12 mg/1 year | Chromatic contrast | 0.03 |
| Kvansakul et al., | 34 adults | RCT | 3 arms of L and Z | Intraocular scatter | + for L (no |
| Loughman et al., | 36 adults | RCT | 24 subjects on L, Z, MZ | VA and CSF measured under glare | 0.006 |
| Loughman et al., | 142 adults | Cross-sectional | n/a | VA and CSF measured under glare, PS recovery | Null* |
| Nolan et al., | 121 adults | RCT | 13 mg, one year | CSF under glare | 0.05 |
| Olmedilla et al., | 17 elderly cataracts patients | RCT | 12 mg, 2 yrs | Glare sensitivity | 0.005 |
|
Renzi and Hammond, | 50 adults | Cross-sectional | n/a | Chromatic contrast | 0.0001 |
| Richer et al., | 90 v, dry AMD patients | RCT | 3 arms, ~10 mg L, one year | Glare questions | 0.10 (ns) |
| Richer et al., | 60 dry AMD patients | RCT | L 9 mg, one year | Glare recovery | 0.01 |
|
Stringham and Hammond, | 36 adults | Cross-sectional | n/a | GD, PS recovery | 0.0001 |
|
Stringham and Hammond, | 40 adults | Intervention (no placebo) | 12 mg/6 mos | GD, PS recovery | 0.0001 |
| Stringham et al., | 26 adults | Cross-sectional | n/a | CSF measured under glare, PS recovery | 0.0001 |
| Yao et al., | 120 adults | RCT | 20 mg L, one year | CSF under glare, glare Qs | CSF (0.05), |
CSF: contrast sensitivity function; GD: glare disability threshold; PS: photostress; RCT: placebo-controlled randomized trial.
*All patients were adults. These studies used glare sources (halogen or tungsten) with little or no short-wave energy and/or clinical tests with low discriminative ability [38].